[1] Karime C, Wang J, Woodhead G, et al. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma.?Expert Opin Investig Drugs. 2022;31(1):1-13. DOI:
10.1080/13543784.2022.2019706[2] Haymaker C, Johnson DH, Murthy R, et al. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.?Cancer Discov. 2021;11(8):1996-2013. DOI:
10.1158/2159-8290.CD-20-1546 